Industry

New data from pooled analysis shows DecisionDx®-Melanoma can identify patients at a high risk of melanoma recurrence within a patient population deemed low risk (T1, ≤1mm) by traditional staging systems Survey of 400 dermatologic clinicians demonstrates how DecisionDx®-SCC results can lead to risk-aligned treatment plan changes for patients with high-risk squamous cell carcinoma Castle’s laboratory … [Read more…]

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Takeda (TSE:4502/NYSE:TAK) today announced that it has signed a 15-year lease with BioMed Realty for approximately 600,000 square feet of research and development (R&D) and office space to be built at 585 Third Street in Kendall Square. The state-of-the-art facility will allow Takeda, the largest life sciences employer in Massachusetts, to create a … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Digital Migraine Treatment Devices Market Research Report by Product Type, Application, Region – Global Forecast to 2027 – Cumulative Impact of COVID-19” report has been added to ResearchAndMarkets.com’s offering. The Global Digital Migraine Treatment Devices Market size was estimated at USD 308.27 million in 2021, USD 344.63 million in 2022, and is projected … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Arthritis Monoclonal Antibodies Global Market Report 2022: By Drug, By Application, By End-Use” report has been added to ResearchAndMarkets.com’s offering. Arthritis Monoclonal Antibodies Global Market Report 2022 provides the strategists, marketers and senior management with the critical information they need to assess the global arthritis monoclonal antibodies (mab’s) market. This report focuses on … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Heavy Metal Poisoning Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update” report has been added to ResearchAndMarkets.com’s offering. The pipeline guide provides comprehensive information on the therapeutics under development for Heavy Metal Poisoning (Toxicology), complete with analysis by stage of development, drug target, mechanism of action … [Read more…]

PARIS & BAGSVÆRD, Denmark–(BUSINESS WIRE)–#NAFLD—Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, today announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders. NASH is a chronic metabolic liver disease that affects … [Read more…]

Deal will fuel continued growth at U.K.-based, sample-management software company, which improves research processes for critical biotech, pharmaceutical and academic organizations BOSTON–(BUSINESS WIRE)–#industrialtech–Battery Ventures, a global, technology-focused investment firm, announced a significant, majority investment in Titian Software Ltd., a U.K. company that develops innovative sample-management software and related services for life-sciences laboratories. Specific terms were … [Read more…]

CAMBRIDGE, England–(BUSINESS WIRE)–Congenica, a digital health company that enables precision medicine through its world-leading diagnostic decision support platform for genomic data, today announces the appointment of Robert Denison as Chief Executive Officer (CEO). He will also join the Board of the company. Rob has a strong history of growing businesses ranging from start-ups through to … [Read more…]

Prurigo nodularis is a rare, potentially debilitating, inflammatory skin disease characterized by disfiguring skin nodules often covering extensive areas of the body, and an intense and chronic itch There are currently no approved therapeutic options Nemolizumab is a first-in-class investigational monoclonal antibody that blocks the signaling of IL-31, a key neuroimmune cytokine involved in the … [Read more…]

Application based on DESTINY-Breast04 results that showed Daiichi Sankyo and AstraZeneca’s trastuzumab deruxtecan demonstrated superior progression-free and overall survival versus chemotherapy TOKYO & MUNICH–(BUSINESS WIRE)–Daiichi Sankyo (TSE: 4568) today announced that the European Medicines Agency (EMA) has validated the Type II Variation application for trastuzumab deruxtecan as monotherapy for the treatment of adult patients with … [Read more…]